Share this article on:

Enhanced Drug Delivery to the Skin Using Liposomes

Blueschke, Gert, MD*; Boico, Alina, MSc; Negussie, Ayele H., PhD; Yarmolenko, Pavel, PhD‡,§; Wood, Bradford J., PhD; Spasojevic, Ivan, PhD; Fan, Ping, MS; Erdmann, Detlev, MD, PhD, MHS*; Schroeder, Thies, PhD†,‖; Sauerbier, Michael, MD, PhD**; Klitzman, Bruce, PhD*,§

Plastic and Reconstructive Surgery – Global Open: July 9, 2018 - Volume Latest Articles - Issue - p
doi: 10.1097/GOX.0000000000001739
Latest Articles: PDF Only

Background: Enhancing drug delivery to the skin has importance in many therapeutic strategies. In particular, the outcome in vascularized composite allotransplantation mainly depends on systemic immunosuppression to prevent and treat episodes of transplant rejection. However, the side effects of systemic immunosuppression may introduce substantial risk to the patient and are weighed against the expected benefits. Successful enhancement of delivery of immunosuppressive agents to the most immunogenic tissues would allow for a reduction in systemic doses, thereby minimizing side effects. Nanoparticle-assisted transport by low temperature–sensitive liposomes (LTSLs) has shown some benefit in anticancer therapy. Our goal was to test whether delivery of a marker agent to the skin could be selectively enhanced.

Methods: In an in vivo model, LTSLs containing doxorubicin (dox) as a marker were administered intravenously to rats that were exposed locally to mild hyperthermia. Skin samples of the hyperthermia treated hind limb were compared with skin of the contralateral normothermia hind limb. Tissue content of dox was quantified both via high-performance liquid chromatography and via histology in skin and liver.

Results: The concentration of dox in hyperthermia-treated skin was significantly elevated over both normothermic skin and liver. (P < 0.02).

Conclusions: We show here that delivery of therapeutics to the skin can be targeted and enhanced using LTSLs. Targeting drug delivery with this method may reduce the systemic toxicity seen in a systemic free-drug administration. Development of more hydrophilic immunosuppressants in the future would increase the applicability of this system in the treatment of rejection reactions in vascularized composite allotransplantation. The treatment of other skin condition might be another potential application.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

From the *Kenan Plastic Surgery Research Labs, Duke University Medical Center, Durham, N.C.

Department of Radiation Oncology, Duke University Medical Center, Durham, N.C.

Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Md.

§Department of Biomedical Engineering, Duke University, Durham, N.C.

PK/PD Bioanalytical Core Laboratory, Department of Medicine, Duke University Medical Center, Durham, N.C.

Department of Physical Chemistry, University of Mainz, Mainz, Germany

**Department of Plastic, Hand and Reconstructive Surgery, Hand Trauma Center, BG Trauma Center Frankfurt am Main, Frankfurt, Germany.

Published online 9 July 2018.

Received for publication July 11, 2017; accepted February 7, 2018.

Supported via internal funding through the Robert Jones Fund (Duke Plastic Surgery). NIH (B. W., A. H. N., P. Y.) has a Cooperative Research and Development Agreement with Celsion Corp. Although similar in composition, Celsion Corp. did not supply the Liposomes used in this study.

Disclosure: The authors have no financial interest to declare in relation to the content of this article. The Article Processing Charge was paid for by the authors.

Products and drugs used for this study: Monostearoyl-2-hydroxy-sn-glycero-3-phosphocholine (MSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (Polyethylene Glycol)2000] (DSPEPEG2000), Genzyme Corporation (Cambridge, MA). Doxorubicin, Bedford Laboratory (Bedford, OH). Rotovap vacuum desiccator, LIPEXTM extruder (Northern Lipids, Burnaby, BC). Nuclepore polycarbonate membrane filters (Whatman PLC, Maidstone, Kent, UK). PD-10 desalting column (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Closed-cell extruded polystyrene (Styrofoam) cups (human grade). Digital thermometer (Omega). Waters 2695 HPLC and Waters 2475 fluorescence detector. Fast-Prep, Thermo Savant (doxorubicin extraction). Leica CM1850 microtome. Zeiss AxioSkop II. Metamorph and ImageJ (NIH) software for imaging and analysis.

Bruce Klitzman, PhD, Kenan Plastic Surgery Research Labs , Duke University Medical Center, Durham, NC 27710, E-mail: klitz@duke.edu

Copyright © 2018 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Plastic Surgeons. All rights reserved.